Last reviewed · How we verify

Surgicel® Original — Competitive Intelligence Brief

Surgicel® Original (Surgicel® Original) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent. Area: Surgery/Hemostasis.

phase 3 Hemostatic agent Surgery/Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Surgicel® Original (Surgicel® Original) — Takeda. Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Surgicel® Original TARGET Surgicel® Original Takeda phase 3 Hemostatic agent
Patients receive microporous polysaccharide hemospheres. Patients receive microporous polysaccharide hemospheres. Fundación para la Investigación del Hospital Clínico de Valencia marketed Topical hemostatic agent
TachoSil TachoSil GATT Technologies BV marketed Hemostatic agent / Fibrin sealant Fibrinogen (conversion to fibrin via thrombin)
chitosan gel chitosan gel Ain Shams University marketed Biopolymer wound dressing / hemostatic agent
Floseal hemostatic matrix Floseal hemostatic matrix Chang Gung Memorial Hospital marketed Hemostatic agent Thrombin-mediated fibrin formation
Pathogen-Reduced Cryoprecipitate Pathogen-Reduced Cryoprecipitate Weill Medical College of Cornell University marketed Blood product / Hemostatic agent
EVARREST™ EVARREST™ Ethicon, Inc. marketed Topical hemostatic agent Fibrinogen (Factor I) and thrombin (Factor IIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agent class)

  1. Chang Gung Memorial Hospital · 1 drug in this class
  2. DeNova Research · 1 drug in this class
  3. Ethicon, Inc. · 1 drug in this class
  4. Mallinckrodt · 1 drug in this class
  5. Sun Yat-sen University · 1 drug in this class
  6. Swiss Cancer Institute · 1 drug in this class
  7. Takeda · 1 drug in this class
  8. WakeMed Health and Hospitals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Surgicel® Original — Competitive Intelligence Brief. https://druglandscape.com/ci/surgicel-original. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: